11:42 AM EST - Acerus Pharmaceuticals : Reported its financial results for the three month period ended June 30, 2016. Revenues for the three months ended June 30, 2016 were $10.6 million compared to $2.7 million in same prior year period. Earnings before interest, tax, depreciation and amortization (“EBITDA”) was a loss of $1.1 million and $1.0 million for second quarter 2016 and 2015 respectively. Acerus Pharmaceuticals
shares T.ASP are trading unchanged at $0.10.
